Company Ocugen, Inc.

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 22/01/2026 am IST			5-day change	1st Jan Change
1.490 ^USD	-10.78%		-20.74%	+10.37%

15/01	Ocugen, Inc. - Special Call
15/01	Ocugen Says Gene Therapy Reduced Lesion Growth by 46% in Eye Disease Trial	MT

Business description: Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

Number of employees: 95

Sales by Activity: Ocugen, Inc.

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Research, Development and Commercialization of its Novel Gene Therapies	42.62T	-	-	60.36L	40.55L

See all business segments

Geographical breakdown of sales: Ocugen, Inc.

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
United States	42.62T	-	-	60.36L	40.55L

See all geographic segments

Executive Committee: Ocugen, Inc.

Manager	Title	Age	Since
Shankar Musunuri CEO	Chief Executive Officer	62	27/09/2019
Ramesh Ramachandran DFI	Director of Finance/CFO	57	14/11/2024
Jesse Simmers CTO	Chief Tech/Sci/R&D Officer	-	-
Huma Qamar CTO	Chief Tech/Sci/R&D Officer	42	18/03/2024
Arun Upadhyay CTO	Chief Tech/Sci/R&D Officer	44	01/12/2020

See OCUGEN, INC. governance

Composition of the Board of Directors: Ocugen, Inc.

Director	Title	Age	Since
C. Satish Chandran BRD	Director/Board Member	70	05/06/2025
Shankar Musunuri CHM	Chairman	62	27/09/2019
Blaise Coleman BRD	Director/Board Member	52	05/06/2025
Uday Kompella BRD	Director/Board Member	59	01/09/2013
Junge Zhang BRD	Director/Board Member	59	01/09/2019
Kirsten Castillo BRD	Director/Board Member	53	05/04/2020

Composition of the Board of Directors

Shareholders: Ocugen, Inc.

Name	Equities	%	Valuation
Janus Henderson Investors US LLC 6.404 %	2,00,00,000	6.404 %	27 M $
Vanguard Fiduciary Trust Co. 4.874 %	1,52,23,585	4.874 %	21 M $
Shankar Musunuri 1.954 %	61,01,223	1.954 %	8 M $
Millennium Management LLC 1.333 %	41,62,149	1.333 %	6 M $
GMT Capital Corp. 1.33 %	41,53,798	1.33 %	6 M $

List of OCUGEN, INC. shareholders

Company details: Ocugen, Inc.

Ocugen, Inc.

11 Great Valley Parkway

19355, Malvern

http://www.ocugen.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
OCUGEN, INC.	-10.78%	-20.74%	+98.75%	+23.14%	47Cr
LONZA GROUP AG	+0.72%	+0.65%	-1.51%	+13.45%	4.93TCr
IQVIA HOLDINGS INC.	+3.30%	+0.02%	+17.36%	+7.96%	4.11TCr
BEONE MEDICINES AG	+2.20%	-1.47%	+56.21%	+28.23%	3.78TCr
CELLTRION, INC.	-1.45%	-7.69%	+17.41%	+37.09%	3.05TCr
REVOLUTION MEDICINES, INC.	+1.13%	-3.04%	+192.65%	+327.07%	2.27TCr
MEDPACE HOLDINGS, INC.	+3.02%	+0.67%	+78.58%	+170.83%	1.75TCr
Average	-0.27%	-3.97%	+65.64%	+86.83%	2.85TCr
Weighted average by Cap.	+1.42%	-1.11%	+45.60%	+68.29%